Acinetobacter Species Infections Among Navy and Marine Corps Beneficiaries: 2013 Annual Report
Annual rept. 1 Jan-31 Dec 2013
NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA
Pagination or Media Count:
Since the early 2000s, health professionals increasingly are concerned about Acinetobacter species infections due to demonstrated ability to develop resistance to multiple antibiotics, limiting treatment options. In 2013, Acinetobacter incidence was 5.5 and 4.4 per 100,000 persons per year in the Department of the Navy DON and the Department of Defense DOD, respectively, continuing previously observed descending trends. Active duty Marines had a higher prevalence rate than any other group of service members. A. baumannii was the most common etiologic agent in 2013 was, differing slightly from 2012. In the DON, a negligible increase in overall resistance was noted, though there was an increase in XDR cases. For non-MDR cases in the DON and DOD, providers often prescribed trimethoprimsulfamethoxazole, consistent with 2012 observations. For MDRXDR cases in 2013, DON providers most commonly prescribed colistin, minocycline, piperacillintazobactam, and trimethoprimsulfamethoxazole. DOD providers most commonly prescribed ciprofloxacin for these cases. Although different from 2012, 2013 prescribing patterns were consistent with recommendations. Among DON and DOD beneficiaries respectively, organisms were most susceptible to cefepime and gentamicin while least susceptible to ampicillin and nitrofurantoin consistent with observations for the DON and DOD from 2012.
- Medicine and Medical Research